EpCAM+ CTCs could also aid to assess the optimal surgical margin size during LR [62], optimizing the management of HCC patients on the waiting list for LT [76], and for a better selection of candidates to certain therapies [61]. This evidence concerns the gene EPCAM and hepatocellular carcinoma.